Nicotine Science and Policy
By Harry Shapiro Aug. 13, 2026
Harry's blog 134: Filtering out lies and misinformation
The only major global journal focused on harm reduction has gone bust. Since 2017, Filter has advocated through journalism for rational and compassionate approaches to drug use, drug policy and human rights, while also standing out for its coverage of tobacco harm reduction. Its closure is a significant loss - particularly at a time when well-funded opponents of tobacco harm reduction continue to thrive.
September 14, 2026 by gfn.tv
Why Is Harm Reduction Different for Smokers?
Harm reduction feels different for smokers because tobacco control has often treated nicotine use as a moral problem rather than a risk continuum. People who smoke need realistic ways to reduce exposure to the harms of combustion, especially after repeated quit attempts. Safer nicotine products do not remove every risk, but they can change the scale of harm dramatically. Public health should meet smokers with practical options, not only expectations of abstinence.
September 14, 2026 by github.io
How Australia has Lost Control of the Nicotine Market?
Australia’s nicotine policy has become a case study in disinformation with real-world consequences. Smokers are told to quit, yet lower-risk alternatives are restricted, misrepresented or pushed into channels with less oversight. That confusion protects cigarettes more than it protects public health. Evidence-based communication should explain relative risk clearly, support adult switching and stop treating harm reduction as a threat to tobacco control.
September 14, 2026 by substack.com
Why Is Your Patient Still Smoking Cigarettes?
A patient who still smokes is not a failure of character. It may be a sign that the advice, tools or assumptions around quitting are not meeting the reality of dependence. Clinicians can make a difference by asking what has already been tried, what keeps the cigarette in place, and whether lower-risk nicotine options could support a move away from combustion. Smoking cessation works better when care starts with the person, not the expectation that one method should work for everyone.
14.10% of the adult population are current smokers. There are approximately 39.8 million current smokers in United States 17.10% of men are current smokers but only 11.10% of women.
SOURCE: GSTHR
September 11, 2026 by vapingpost.com
Some Sense at Last? Coalition Proposes 80% Tobacco Tax Cut and Legal Vapes to Break Australia’s Black Market
In line with what tobacco harm reduction experts have been suggesting all along, Australia’s opposition party wants to slash tobacco taxes and legalise regulated vapes and nicotine pouches to undermine the country’s booming black market.
September 11, 2026 by eichor.com
Multi-Site Trial of Tirzepatide for Smoking Cessation
This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of (...)
Blogs
Harry's blog 134: Filtering out lies and misinformation
The only major global journal focused on harm reduction has gone bust. Since 2017, Filter has advocated through journalism for rational and compassionate approaches to drug use, drug policy and human rights, while also standing out for its coverage of tobacco harm reduction. Its closure is a significant loss - particularly at a time when well-funded opponents of tobacco harm reduction continue to thrive.
Harry’s blog 133: Silence is consent
Two tobacco control consultations that demand your attention
I’m sure there are many of you like me who are deeply cynical about public consultations. They often feel like political tick box exercises allowing the issuing authority from local councils to international organisations to say they have ‘consulted with the people’, when in truth they knew exactly what they were going to do from the get-go.
Harry’s Blog 132: “Zyn! Went The Strings Of My Heart” (with apologies to Judy Garland)
FDA approval of 20 nicotine pouch products is another step forward for tobacco harm reduction
The FDA in the U.S. has granted marketing authorisation for Zyn nicotine pouch products (five variations on mint plus five other flavours in two different strengths).
In its letter to PMI (who own Zyn manufacturers Swedish Match), the FDA wrote:
Based on our review of your MRTPAs [Modified Risk Tobacco Applications] we determined that the proposed modified risk tobacco products, …as actually used by consumers would significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole, taking into account both users of tobacco products and persons who do not currently use tobacco products. Therefore, we authorize marketing of the tobacco products as modified risk tobacco products with the following modified risk information – “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis”.